Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena Pollack

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Diabetes, Obesity & Metabolism|January 13, 2026
Risk of recurrent diabetic ketoacidosis following initiation of sodium-glucose co-transporter 2 inhibitors in patients with an insulin-deficient diabetes and prior diabetic ketoacidosis: An observational cohort studyAnat Tsur, Omer Hamtzany, Rena Pollack, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: A real world analysisAnat Tsur, Avivit Cahn, Lior Hanoch, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2021
PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIESRena Pollack, Maayan Kagan, Rivka Dresner-Pollak, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2019
Association of Inpatient Glucose Measurements With Amputations in Patients Hospitalized With Acute Diabetic FootShahar Peled, Rena Pollack, Ofer Elishoov, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|January 31, 2026
Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetesTehila Shlomov, Itay Nitzan, Rena Pollack, et al.
Pathology Oncology Research : POR|May 4, 2023
Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patientsAdi Horesh, Rena Pollack, Hovav Nechushtan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 20, 2021
Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective StudyAnat Tsur, Elchanan Dreyfuss, Rosane Ness-Abramof, et al.
Diabetes, Obesity & Metabolism|June 19, 2025
Predictors of diabetic ketoacidosis in patients with insulin-deficient diabetes phenotype initiating SGLT2 inhibitorsAnat Tsur, Gil Leibowitz, Matan J Cohen, et al.
Diabetes, Obesity & Metabolism|September 13, 2018
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysisAvivit Cahn, Cheli Melzer-Cohen, Rena Pollack, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2022
Consistency of Thyroid Imaging Reporting and Data System Reporting in Community-Based Imaging Centers Versus a Large Tertiary HospitalRena Pollack, Noam Koch, Haggi Mazeh, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|January 13, 2026
Risk of recurrent diabetic ketoacidosis following initiation of sodium-glucose co-transporter 2 inhibitors in patients with an insulin-deficient diabetes and prior diabetic ketoacidosis: An observational cohort studyAnat Tsur, Omer Hamtzany, Rena Pollack, et al.
Diabetes, Obesity & Metabolism|March 14, 2025
Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: A real world analysisAnat Tsur, Avivit Cahn, Lior Hanoch, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 21, 2021
PD-L1 EXPRESSION IN NORMAL ENDOCRINE TISSUES IS NOT INCREASED DESPITE HIGH INCIDENCE OF PD-1 INHIBITOR-ASSOCIATED ENDOCRINOPATHIESRena Pollack, Maayan Kagan, Rivka Dresner-Pollak, et al.
The Journal of Clinical Endocrinology and Metabolism|June 28, 2019
Association of Inpatient Glucose Measurements With Amputations in Patients Hospitalized With Acute Diabetic FootShahar Peled, Rena Pollack, Ofer Elishoov, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|January 31, 2026
Association between semaglutide use and thyroid eye disease-related outcomes in autoimmune thyroiditis with type II diabetesTehila Shlomov, Itay Nitzan, Rena Pollack, et al.
Pathology Oncology Research : POR|May 4, 2023
Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patientsAdi Horesh, Rena Pollack, Hovav Nechushtan, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 20, 2021
Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective StudyAnat Tsur, Elchanan Dreyfuss, Rosane Ness-Abramof, et al.
Diabetes, Obesity & Metabolism|June 19, 2025
Predictors of diabetic ketoacidosis in patients with insulin-deficient diabetes phenotype initiating SGLT2 inhibitorsAnat Tsur, Gil Leibowitz, Matan J Cohen, et al.
Diabetes, Obesity & Metabolism|September 13, 2018
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysisAvivit Cahn, Cheli Melzer-Cohen, Rena Pollack, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2022
Consistency of Thyroid Imaging Reporting and Data System Reporting in Community-Based Imaging Centers Versus a Large Tertiary HospitalRena Pollack, Noam Koch, Haggi Mazeh, et al.
Pageof 3